Physician profile
Corey Chamness
NPI 1659714756
$1,704.32
in general payments reported to CMS, 2019-2025
19 companies · $876 in 2025
The $876 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $24.05 · 2024: $804 · 2025: $876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,704.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,704.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $941.25 | 2023-2025 | Ubrelvy |
| Astellas Pharma US INC | $146.31 | 2024-2025 | Veozah |
| Pfizer INC. | $75.68 | 2024-2025 | |
| Intra-Sana Laboratories | $68.77 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.84 | 2024-2025 | Xifaxan |
| Antares Pharma, INC. | $62.71 | 2024-2025 | Xyosted |
| Astrazeneca Pharmaceuticals Lp | $56.90 | 2024-2025 | Airsupra |
| Otsuka America Pharmaceutical, INC. | $39.36 | 2025 | Rexulti |
| Lilly USA, LLC | $38.56 | 2025 | Mounjaro, Zepbound |
| Galderma Laboratories, L.P. | $34.07 | 2025 | |
| Amneal Pharmaceuticals LLC | $29.26 | 2024 | Unithroid |
| Abiomed | $23.76 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.91 | 2025 | Caplyta |
| Boston Scientific Corporation | $20.17 | 2025 | Wavewriter Alpha Prime 16 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.20 | 2024 | Jardiance |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $18.06 | 2025 | Repatha, Otezla |
| Pharmacosmos Therapeutics INC. | $15.69 | 2025 | Monoferric |
| Takeda Pharmaceuticals U.S.A., INC. | $15.31 | 2025 | Trintellix |
| Currax Pharmaceuticals LLC | $13.51 | 2024 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corey Chamness listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.